INSPIRED MOMENTUM. NOW. WELCOME TO AKCEA.

A company committed to transforming cardiometabolic lipid disorders.

News

11/15/2016 Ionis Pharmaceuticals Reports Positive Clinical Data from IONIS-ANGPTL3-L Rx

09/22/2016 Akcea Announces Publication in The Lancet of Clinical Results with Lp(a)-Lowering Drugs Designed to Treat Cardiovascular Disease

09/15/2016 Akcea Therapeutics Announces Presentations of New Data Underscoring Burden of Disease in Familial Chylomicronemia Syndrome

07/28/2016 Akcea Therapeutics Receives Orphan Designation in Europe for Volanesorsen for the Treatment of Familial Partial Lipodystrophy (FPL)

06/29/2016 Akcea Therapeutics Announces Launch of IN-FOCUS, a Research Study to Assess Impact of Familial Chylomicronemia Syndrome

06/27/2016 Akcea Announces Publication of Positive Volanesorsen Clinical Data Showing Reduced Triglycerides and Improved Insulin Sensitivity in Patients with High Triglycerides and Type 2 Diabetes

05/16/2016 Akcea Therapeutics Announces Completion of Enrollment in Phase 3 COMPASS Trial of Volanesorsen

04/06/2016 Akcea Therapeutics to Present at 15th Annual Needham Healthcare Conference

03/31/2016 Akcea Therapeutics Supports World Lipodystrophy Day

03/04/2016 Akcea Therapeutics to Present at the Cowen and Company 36th Annual Health Care Conference

01/27/2016 Patient Voices: Dear FCS

01/22/2016 New Treatment Option for Patients Severely High Triglyceride Levels

01/19/2016 Akcea Therapeutics Appoints Louis St. L. O'Dea as Chief Medical Officer

01/14/2016 Q&A: RNA therapies aimed at solving cardiometabolic and lipid disorders

11/08/2015 Ionis Pharmaceuticals Reports Positive Clinical Data From Lp(a) Lowering Drugs

11/06/2015 Newly Published Data Provide Evidence that Elevated Lp(a) and Associated Oxidized Phospholipids Predict the Progression of Aortic Stenosis

11/05/2015 Ionis Pharmaceuticals and Akcea Therapeutics Announce Start of Phase 3 Study of Volanesorsen in Patients with Familial Partial Lipodystrophy

10/06/2015 Newly Published Data Provide Evidence that Elevated Lp(a) and Associated Oxidized Phospholipids Predict the Progression of Aortic Stenosis

09/11/2015 Leading Medical Journals Publish Results from Volanesorsen Phase 2 Program

07/29/2015 Positive Clinical Data From Volanesorsen Published in the New England Journal of Medicine

07/22/2015 Positive Clinical Data From Lp(a) Lowering Drug IONIS-APO(a) Rx Published in The Lancet

07/06/2015 Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (IONIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome

05/28/2015 Webcast Alert: Akcea Therapeutics Conference Call

MULTIPLE DISEASES.
FOCUSED APPROACH.

Our pipeline has the potential to change the approach to treating cardiometabolic lipid disorders, improving patients' lives and helping their physicians provide better care, in the near-term and over the course of the coming years.

PRE-CLINICAL PHASE 1 PHASE 2 PHASE 3
IONIS-APO(a)-LRX

Calcific Aortic Stenosis with High Lp(a)

CVD with High Lp(a)

Mixed Dyslipidemias

IONIS-APOCIII-LRX

Severe High Triglycerides (SHTG)

High Triglycerides with Type 2 Diabetes

WHY NOT YOU?

At Akcea, you can help build a new company, create a vibrant culture, and help bring forward therapies with the potential to change patients' lives.

Our unique culture. Your unique opportunity.

Director/Executive Director, Regulatory Affairs

The Director/Executive Director, Regulatory Affairs will be a key driver of developing regulatory strategy and be an active partner in drug development project planning and execution. This individual will work within cross-company development project teams and will provide expertise in translating clinical, nonclinical and CMC regulatory requirements into practical strategic regulatory plans. This individual will implement these plans through coordination, authorship and development of domestic and international drug applications and submissions, and through regulatory agency interactions.

Please visit here for more information. Reference Requisition #15-0103

Head, Drug Safety And Pharmacovigilance

Akcea has drugs in all phases of clinical development and is looking for an experienced Safety and Pharmacovigilance Physician to join us in our Cambridge, MA, offices and build and lead our drug safety programs.

Please visit here for more information. Reference Requisition #15-0107

Explore other career opportunities

Leadership

Paula Soteropoulos

Paula SoteropoulosPresident and Chief Executive Officer

A global strategic and operating management executive with over 25 years' success at building high-performance global teams, leading complex development programs from early stage through approval, and commercializing global products.

Jeffrey M. Goldberg

Jeffrey M. Goldberg Chief Operating Officer

Experienced biotech program and brand leader with nearly 20 years of experience. Drove programs from discovery and pre-clinical through IND, clinical trials, NDA, and commercialization/marketing in multiple therapeutic areas, including oncology, neurology, renal, and other rare/orphan diseases.

Molly Harper

Molly Harper VP, Commercial Development

Experienced commercial leader with over 15 years of experience in the life sciences, with expertise in pre-launch market development and commercial operations for biopharmaceuticals.

Andres Digenio, MD, PhD

Louis St. L. O'Dea MB BCh BAO. FRCP(C) Chief Medical Officer

Board-certified physician and 22-year industry professional with a track record of successful global drug development and regulatory approvals. Dr. O’Dea has led 13 clinical NDAs, 4 orphans and 1 device approval and is experienced with proteins, peptides, small molecules and nucleotides, as well as with a broad range of devices and routes of administration.

SCIENTIFIC ADVISORY BOARD

World-class dyslipidemia experts guide Akcea development programs.

John Kastelein, MC, PhD, FESC Professor of Medicine, Chairman of the Department of Vascular Medicine, Academic Medical Center, University of Amsterdam

Dr John Kastelein

Professor Kastelein is a recognized world leader in the studies focusing on the significance of lipoprotein metabolism in the development of atherosclerotic vascular disease. Prof. Kastelein's current research interests focus on the etiology, diagnosis, prevention, and treatment of hypertriglyceridemia, hypercholesterolemia, and low HDL cholesterol, all conditions associated with atherosclerosis and cardiovascular disease. He has published over 740 research papers in peer-reviewed journals, including Nature Genetics, Lancet, New England Journal of Medicine, JAMA, and Circulation. His Hirsch index is 82; and his total citations are more than 23,000.

Joseph Witztum, MD Professor of Medicine, Department of Medicine and Director, Atherosclerosis Research Group, University of California, San Diego

Dr Joseph Witztum

Dr Witztum is a Distinguished Professor of Medicine in Endocrinology/Metabolism at UCSD in La Jolla, where he continues to see patients in his Lipid Research Clinic. He is internationally recognized for his research into the pathogenesis of atherosclerosis and directs a group of investigators studying both basic mechanisms, as well as novel approaches to diagnosis and therapy of atherosclerosis in humans. He pioneered the concept of the role of oxidized LDL (OxLDL) in the pathogenesis of atherosclerosis, studies that place OxLDL central to an understanding of atherogenesis. Besides his basic research studies, he has remained active in clinical lipidology and has been a member of national consensus panels. Dr Witztum has published more than 400 scientific manuscripts and papers and is an ISI Most Highly Cited Author. He has been an Associate Editor of multiple journals and is currently Editor-in-Chief of the Journal of Lipid Research.

Sotirios (Sam) Tsimikas, MD Professor of Medicine and Director of Vascular Medicine at the University of California San Diego, Vice President, Clinical Development, Ionis Pharmaceutical, Inc.

Dr Sotirios (Sam) Tsimikas

Dr Tsimikas obtained his MD degree in 1988 from the University of Massachusetts Medical School and completed his Internal Medicine training at the University of Massachusetts Medical Center in 1991. He completed separate fellowships in Cardiovascular Disease, Atherosclerosis, and Interventional Cardiology at the University of California, San Diego, from 1992-1997. Dr Tsimikas' clinical interests are focused in his role as Director of the Vascular Medicine Program that encompasses treating a wide variety of patients in the continuum of high-risk primary prevention to endovascular intervention. Areas of interest include evaluating and treating patients with elevated Lp(a) levels and percutaneous coronary and peripheral interventions. This program also functions as a key teaching venue for general and interventional cardiology fellows. Dr Tsimikas has published over 195 articles and book chapters, including in NEJM, Cell, Nature, JACC, JCI, Circulation, Circ Res, ATVB, and EHJ. He is Fellow of the American College of Cardiology, the American Heart Association, and the Society for Cardiac Angiography and Interventions.

Rosanne Crooke, PhD Vice President, Cardiovascular Disease Antisense Drug Discovery, Ionis Pharmaceuticals

Dr Rosanne Crooke

Under Dr Crooke's leadership, the CV/Metabolic research program has demonstrated that antisense technology can be used to create multiple drugs to treat CV and metabolic diseases. The vast pipeline of drugs created by this program include Kynamro, an antisense inhibitor to human apoB-100 that is approved for the treatment of HoFH and is completing registration studies in HoFH. Dr Crooke received her PhD at the University of Pennsylvania in 1986 and has progressed to steadily more senior positions at Ionis. She is an expert in RNA-targeted therapeutics and cardiovascular and metabolic drug discovery. She has authored more than 85 scientific publications and is an inventor on nearly 70 patents and patent applications.

References 1. Gaudet D, Brisson D, Tremblay K, et al. Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med. 2014;371:2200-6. 2. Hung M-Y, Tsimikas S. What is the ultimate test that lowering lipoprotein(a) is beneficial for cardiovascular disease and aortic stenosis? Curr Opin Lipidol. 2014;25:1-8. 3. Handelsman Y, Bloomgarden ZT, Garber AJ, et al. The clinical approach to the detection of lipodystrophy–an AACE consensus statement. Endocr Pract. 2013;19:107-16. 4. Crooke RM, Graham MJ. Therapeutic potential of antisense oligonucleotides for the management of dyslipidemia. Clin Lipidol. 2011;6:675-692. 5. Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123:2292-2333. 6. Data on file. Akcea Pharmaceuticals Inc. 7. Minicocci I, Santini S, Cantisani V, et al. Clinical characteristics and plasma lipids in subjects with familial combined hypolipidemia: a pooled analysis. J Lipid Res. 2013;54:3481-90. 8. Ooi EMM, Barrett HG, Chan DC, Watts GF. Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. Clin Sci. 2008;114:611-624.